Lerodalcibep
Intervention1 paper3 findings
Outcomes
2Apolipoprotein B
downin humans1
1 study
Apolipoprotein B
downin humans1
Lerodalcibep decreases Apolipoprotein B in humans.
Reviewin patients with hypercholesterolemia
Lerodalcibep-liga as an Injectable Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)-Targeted Therapy for Patients With Hypercholesterolemia · The Annals of pharmacotherapy · 25 Sep 2026
LDL cholesterol
downin humans1
1 study
LDL cholesterol
downin humans1
Lerodalcibep decreases LDL cholesterol in humans (50% to 65%).
Reviewin patients with heterozygous familial hypercholesterolemia, established cardiovascular disease, or high cardiovascular riskmonthly
Lerodalcibep-liga as an Injectable Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)-Targeted Therapy for Patients With Hypercholesterolemia · The Annals of pharmacotherapy · 25 Sep 2026
Associations
1Injection-site reactions
upin humans1
1 study
Injection-site reactions
upin humans1
Lerodalcibep raises the risk of injection-site reactions in humans.
Reviewin comparison with placebo
Lerodalcibep-liga as an Injectable Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)-Targeted Therapy for Patients With Hypercholesterolemia · The Annals of pharmacotherapy · 25 Sep 2026